Corvus Pharmaceuticals Inc Working Capital to Net Assets Ratio
Corvus Pharmaceuticals Inc working capital to net assets ratio. Corvus Pharmaceuticals Inc (CRVS) has a Working Capital to Net Assets ratio of 92.0% as of June 2026. Working capital of $207.29 Million (current assets of $220.97 Million minus current liabilities of $13.67 Million) is measured against net assets of $225.33 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check CRVS tangible net assets ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Corvus Pharmaceuticals Inc (2014–2025)
Working capital to net assets ratio of Corvus Pharmaceuticals Inc from 2014 to 2025. This chart shows how Corvus Pharmaceuticals Inc's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of June 2026, the ratio stands at 92.0%, reflecting working capital of $207.29 Million against net assets of $225.33 Million USD. See Corvus Pharmaceuticals Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Corvus Pharmaceuticals Inc Working Capital to Net Assets Ratio by Year (2014–2025)
Corvus Pharmaceuticals Inc working capital to net assets ratio by year from 2014 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Corvus Pharmaceuticals Inc from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see CRVS current and non-current assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 79.8% | $48.83 Million | $61.20 Million | $58.21 Million | $9.38 Million | ▲ +21.4 pp |
| 2024 | 58.4% | $19.00 Million | $32.57 Million | $54.41 Million | $35.40 Million | ▲ +3.8 pp |
| 2023 | 54.5% | $21.09 Million | $38.68 Million | $27.96 Million | $6.87 Million | ▼ -4.1 pp |
| 2022 | 58.7% | $32.91 Million | $56.12 Million | $43.66 Million | $10.75 Million | ▼ -4.8 pp |
| 2021 | 63.4% | $61.62 Million | $97.16 Million | $71.31 Million | $9.69 Million | ▲ +17.4 pp |
| 2020 | 46.0% | $33.19 Million | $72.15 Million | $45.34 Million | $12.15 Million | ▼ -51.2 pp |
| 2019 | 97.2% | $69.12 Million | $71.11 Million | $79.34 Million | $10.22 Million | ▲ +0.5 pp |
| 2018 | 96.7% | $106.70 Million | $110.34 Million | $114.60 Million | $7.90 Million | ▲ +2.3 pp |
| 2017 | 94.4% | $80.11 Million | $84.83 Million | $90.06 Million | $9.94 Million | ▼ -1.6 pp |
| 2016 | 96.0% | $127.55 Million | $132.80 Million | $134.90 Million | $7.35 Million | ▲ +393.8 pp |
| 2015 | -297.7% | $92.59 Million | $-31.10 Million | $95.66 Million | $3.07 Million | ▲ +5900.4 pp |
| 2014 | -6198.1% | $9.86 Million | $-159.00K | $12.53 Million | $2.67 Million | — |